A new study from @biofidelity_dx is examining how its Aspyre technology can bridge the gaps in clinical care that prevent early-stage non-small cell lung cancer (NSCLC) patients from receiving molecular profiling and, as a result, highly effective targeted therapies. “Advancing genomic testing for early-stage resectable NSCLC patients is crucial, and this study offers two opportunities: additional research about actionable mutations in this population and the assessment of a new platform with the potential to improve patient care,” said Dr. Shetal Patel from the University of North Carolina. Click here to learn about how you can join this study and help expand testing options for Early-Stage NSCLC.biofidelity.com/resources/be…